| Literature DB >> 21702980 |
Keivan Majidzadeh-A1, Rezvan Esmaeili, Nasrin Abdoli.
Abstract
BACKGROUND: Biomedical researchers have long looked for ways to diagnose and treat cancer patients at the early stages through biomarkers. Although conventional techniques are routinely applied in the detection of biomarkers, attitudes towards using Real-Time PCR techniques in detection of many biomarkers are increasing. Normalization of quantitative Real-Time PCR is necessary to validate non-biological alteration occurring during the steps of RNA quantification. Selection of variably expressed housekeeping genes (HKs) will affect the validity of the data. The aim of the present study was to identify uniformly expressed housekeeping genes in order to use in the breast cancer gene expression studies. Urokinase Plasminogen Activator was used as a gene of interest.Entities:
Year: 2011 PMID: 21702980 PMCID: PMC3141519 DOI: 10.1186/1756-0500-4-215
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Clinical and histological data of malignant and normal adjacent breast tissues.
| Tissue type | Age | Size (mm) | Tumor stage | grade | Histological type | Menoposal status | ER | PR | Her2/neu | P53 |
|---|---|---|---|---|---|---|---|---|---|---|
| Adjacent | 50 | |||||||||
| Adjacent | 38 | - | - | - | + | |||||
| Malignant | 38 | 18 | IIA | III | IDC | pre | + | + | - | |
| Malignant | 38 | 20 | III | IDC | pre | 3+ | 3+ | 2+ | ||
| Malignant | 58 | 35 | IIIA | II | IDC | post | - | - | - | + |
| Malignant | 80 | 10 | I | IDC | post | + | + | - | ||
| Malignant | 54 | 30 | IIB | II | IDC | post | ||||
| Adjacent | + | + | 3+ | + | ||||||
| Malignant | 40 | 25 | IIB | II | IDC | pre | + | + | - | + |
| Malignant | 35 | 20 | III | IDC | post | |||||
| Adjacent | ||||||||||
| Malignant | + | + | - | + | ||||||
| Malignant | 52 | 21 | IIA | II | IDC | post | + | + | - | + |
| Malignant | III | IDC | + | - | - | + | ||||
| Malignant | 82 | 50 | IIB | III | IDC | post | ||||
| Adjacent | 43 | + | + | - | - | |||||
| Malignant | 50 | 50 | IIA | II | IDC | pre | 3+ | 3+ | - | |
| Malignant | 44 | 20 | IIIA | III | IDC | pre | + | + | - | |
| Malignant | 51 | 20 | IIA | II | IDC | post | ||||
| Malignant | + | + | - | - | ||||||
| Malignant | 37 | 60 | IIIB | II | IDC | post | ||||
| Malignant | 45 | IDC | pre | + | + | - | ||||
| Malignant | 40 | 15 | IB | II | IDC | pre | - | - | - | + |
| Malignant | 42 | 20 | IV | III | IDC | pre | + | + | - | + |
| Malignant | 52 | 21 | IIA | II | IDC | post | + | + | - | - |
| Malignant | 50 | 8 | IIA | II | IDC | post | + | + | - | |
| Malignant | 54 | 30 | IIA | II | IDC | post | - | - | - | - |
| Malignant | 45 | IV | IDC | pre | ||||||
| Adjacent | 45 | |||||||||
| Adjacent | 40 | |||||||||
| Adjacent | 52 | |||||||||
| Adjacent | 42 | - | - | - | - | |||||
| Malignant | 53 | IDC+DCIS | pre | + | + | 3+ | - | |||
| Malignant | 34 | 10 | IIB | II | IDC+DCIS | pre | - | - | - | + |
| Malignant | 56 | 38 | IIB | II | IDC | post | + | + | - | |
| Malignant | 71 | 20 | IV | II | IDC | post | - | - | - | - |
| Malignant | 34 | 30 | IIA | II | IDC | pre | + | + | 3+ | |
| Malignant | 37 | II | IDC | pre | - | - | - | |||
| Malignant | 48 | 30 | IIB | ILC | pre | + | + | - | + | |
| Malignant | 43 | 18 | I | pre | - | + | - | |||
| Malignant | 45 | 20 | II | II | ILC | pre | - | - | 3+ | + |
| Malignant | 39 | 100 | IIIA | II | IDC | pre | ||||
| Malignant | 34 | 60 | III | IDC | pre | |||||
| Malignant | ||||||||||
| Normal | 25 | |||||||||
| Normal | 38 | |||||||||
| Normal | 32 | |||||||||
| Normal | + | + | - | - | ||||||
| Malignant | 50 | 15 | IB | I | IDC | pre | - | - | 3+ | + |
| Malignant | 32 | 10 | IV | II | IDC | pre | + | - | - | |
| Malignant | 60 | 30 | IV | II | IDC | post | + | + | - | - |
| Malignant | 41 | 50 | IV | I | IDC | pre |
Stage grouping are based on American Joint Committee on Cancer (AJCC). Estrogen receptor(ER), progesterone receptor (PR), Her2/neu and P53 status are based on IHC results. Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC)
Primer probe sets.
| Target | Accession No. | Sequence | Melting TM | efficiency |
|---|---|---|---|---|
| GAPDH | NM_001002 | F GAAGGTGAAGGTCGGAGTC | 61.3 | 94 |
| R GGGTGGAATCATATTGGAACA | 63.2 | |||
| P ATTTGGTCGTATTGGGCGCCTGGT | 74.9 | |||
| TFRC | NM_003234 | F ACCGGCACCATCAAGCT | 64.5 | 94 |
| R TGATCACGCCAGACTTTGC | 65.2 | |||
| P TGAAAATTCATATGTCCCTCGTGAGGCT | 72.1 | |||
| RPLP0 | NM_001002 | F CGGACGAGGATATGGGATTTG | 67.2 | 89 |
| R AGAAGTAAGCCTTTATTTCCTTGTTT | 64.7 | |||
| P TCACCAAAAAGCAACCAACTTAGCCAGT | 72 | |||
| GUSB | NM_000181 | F GCGTTCCTTTTGCGAGGAGA | 68.6 | 74 |
| R GGTGGTATCAGTCTTGCTCAA | 64.7 | |||
| P ACCAGGTATCCCCACTCAGTAGCCAAG | 72 | |||
| HPRT1 | NM_000194 | F TGGACTAATTATGGACAGGACTGAA | 64.4 | 103 |
| R GTAATCCAGCAGGTCAGCAA | 62.8 | |||
| P CTTGCTCGAGATGTGATGAAGGAGATGG | 73.7 | |||
| UPA | NM_002658 | F AGGGCAGCACTGTGAAATAGATAAGT | 65.7 | 97 |
| R CATGGTACGTTTGCTGAAGGA | 64.8 | |||
| P TTACCGAGGAAAGGCCAGCACTGACA | 75.3 | |||
| ACTB | NM_001101 | F CAGCAGATGTGGATCAGCAAG | 65.9 | 95 |
| R GCATTTGCGGTGGACGAT | 67.1 | |||
| P AGGAGTATGACGAGTCCGGCCCC | 73.8 |
Probes were labeled with 5' FAM and 3' TAMRA.
threshold cycle (CT) values of endogenous controls and uPA.
| Gene | CT Range | CT Min | CT Max | Mean ± s.e.m |
|---|---|---|---|---|
| RPLP0 | 22.68 | 19.52 | 42.2 | 29.69 ± 0.81 |
| GUSB | 8.61 | 27.59 | 36.2 | 31.99 ± 0.33 |
| TFRC | 15.64 | 25.27 | 40.92 | 31.7 ± 0.5 |
| HPRT1 | 14.25 | 26.42 | 40.67 | 32.61 ± 0.43 |
| ACTB | 14.05 | 16.93 | 30.98 | 25.1 ± 0.5 |
| GAPDH | 19.2 | 22.69 | 41.89 | 29.3 ± 0.5 |
| UPA | 10.65 | 28.13 | 38.78 | 31 ± 0.38 |
Figure 1GeNorm analysis of candidate genes: genes with low Average expression stability M which are plotted in the right side of x-axis indicate greater stability.
Figure 2Determination of the optimal number of ECs for normalization: Inclusion of additional reference gene is not required for pairwise variation values (V value) below 0.15.
Stability values of reference genes using geNorm and NormFinder programs
| geNorm | NormFinder | |||
|---|---|---|---|---|
| 1 | TFRC | 2.846 | TFRC | 0.796 |
| 2 | GUSB | 2.902 | GUSB | 1.007 |
| 3 | ACTB | 2.984 | ACTB | 1.130 |
| 4 | HPRT1 | 3.298 | HPRT1 | 1.799 |
| 5 | GAPDH | 3.538 | GAPDH | 1.984 |
| 6 | RPLP0 | 4.737 | RPLP0 | 2.966 |
Genes with lower number are more stable.